AptarGroup, Inc. Q1 2006 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2006. AptarGroup, Inc. operates in the packaging components industry, developing and manufacturing consumer product dispensing systems. The company is organized into three reporting segments: Beauty & Home, Pharma, and Closures. This filing marks the first quarter of 2006, during which the company adopted SFAS 123(R) regarding share-based payment accounting, requiring the recognition of stock option compensation as an expense.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $375.5 million | $344.0 million |
| Operating Income | $32.4 million | $34.3 million |
| Net Income | $19.8 million | $22.1 million |
| Diluted EPS | $0.55 | $0.60 |
| Operating Margin | 8.6% | 10.0% |
| Net Cash from Operations | $31.5 million | $31.8 million |
| Cash and Equivalents | $120.2 million | $144.9 million (Q1 2005) |
| Total Debt (Short & Long Term) | $265.7 million | $246.6 million (Dec 31, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% year-over-year, driven by acquisitions ($25.6 million contribution) and price increases. However, a stronger U.S. dollar negatively impacted sales translation by approximately 5%.
- Profitability Decline: Operating income decreased by $2.0 million and Net Income decreased by $2.3 million. The primary driver was the adoption of SFAS 123(R), which resulted in $7.1 million of stock option expense recorded in the quarter.
- Segment Performance:
- Beauty & Home: Sales up 9%; Segment Income up 11.7% to $16.6 million.
- Closures: Sales up 11%; Segment Income up 28% to $10.5 million.
- Pharma: Sales up 6%; Segment Income up 5% to $17.1 million.
- Acquisitions: Acquired CCL Dispensing Systems, LLC for approximately $21.3 million in cash, adding $9.5 million in goodwill.
Guidance, Outlook, and Risks
- Q2 2006 Outlook: Management expects diluted earnings per share to range between $0.70 and $0.75. This guidance includes an estimated negative impact of $0.04 per share from stock option expenses.
- Sales Outlook: Sales are expected to increase in Q2 despite currency headwinds. The Closures segment is expected to benefit from the full quarter impact of the CCL acquisition. Pharma sales are expected to decline due to lower custom tooling sales.
- Cost Pressures: Raw material costs, particularly plastic resin, are expected to rise. The company faces risks in passing these costs to customers.
- Key Risks: Significant exposure to foreign currency exchange rates (primarily Euro), raw material availability and pricing, competition from Asia, and the successful integration of recent acquisitions.
Investor Verification Checklist
- Stock Option Expense Impact: Verify the sustainability of operating margins given the new $7.1 million quarterly charge for stock-based compensation under SFAS 123(R).
- Currency Hedging: Review the effectiveness of hedging strategies given the 5% negative sales impact from the strong U.S. dollar and the company's significant European operations.
- Acquisition Integration: Monitor the integration of CCL Dispensing Systems and its contribution to the Closures segment's 28% income growth.
- Raw Material Pass-Through: Assess the company's ability to pass rising resin costs to customers without losing market share.
- Debt Levels: Note the increase in total debt to $265.7 million to finance the CCL acquisition and capital expenditures.